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Background: Somatostatin receptors (SSTRs) and opioid receptors (ORs) belong to the superfamily of G-protein
coupled receptors and function as negative regulators of cell proliferation in breast cancer. In the present study, we
determined the changes in SSTR subtype 2 (SSTR2) and μ, δ and κ-ORs expression, signaling cascades and
apoptosis in three different breast cancer cells namely MCF-7, MDA-MB231 and T47D.
Methods: Immunocytochemistry and western blot analysis were employed to study the colocalization and changes
in MAPKs (ERK1/2 and p38), cell survival pathway (PI3K/AKT) and tumor suppressor proteins (PTEN and p53) in
breast cancer cell lines. The nature of cell death upon activation of SSTR2 or OR was analysed using flow cytometry
analysis.
Results: The activation of SSTR2 and ORs modulate MAPKs (ERK1/2 and p38) in cell dependent and possibly
estrogen receptor (ER) dependent manner. The activation of tumor suppressor proteins phosphatase and tensin
homolog (PTEN) and p53 antagonized the PI3K/AKT cell survival pathway. Flow cytometry analyses reveal increased
necrosis as opposed to apoptosis in MCF-7 and T47D cells when compared to ER negative MDA-MB231 cells.
Furthermore, receptor and agonist dependent expression of ORs in SSTR2 immunoprecipitate suggest that SSTR2
and ORs might interact as heterodimers and inhibit epidermal growth factor receptor phosphorylation.
Conclusion: Taken together, findings indicate a new role for SSTR2/ORs in modulation of signaling pathways
involved in cancer progression and provide novel therapeutic approaches in breast cancer treatment.
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Somatostatin (SST) is a multifunctional growth hormone
inhibitory neuropeptide, regulating different arrays of
functions in the brain, endocrine and exocrine tissues.
One of the prominent functions of SST is the negative
regulation of cell proliferation in normal as well as
pathological conditions including pituitary, pancreatic
and breast tumors [1-5]. The anti-proliferative effects of
SST occur indirectly through the inhibition of growth
factors such as insulin growth factor-1 and epidermal
growth factor and angiogenesis [6-9]. The direct anti-
proliferative effect of SST is by binding to seven trans-
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reproduction in any medium, provided the orsomatostatin receptors 1–5 (SSTR1-5). This direct effect
of SST is either cytostatic (cell cycle arrest) or cytotoxic
(apoptosis) [2,10-12]. SSTR1-5 subtypes are variably
expressed in various human tumors including breast
cancer tissues and cells [4,12,13]. We have previously
shown a significant correlation between mRNA and pro-
tein expression of SSTRs with histological tumor
markers as well as with expression levels of estrogen re-
ceptors (ER) and progesterone receptors [4]. These re-
sults indicate that the presence of hormone receptors
might play crucial role on SSTR effectiveness in breast
cancer.
SST and SSTRs are highly expressed in breast cancer
cells as well as autopsied breast tissue. However, SSTR2
is the prominent receptor subtype expressed ubiqui-
tously and abundantly in breast tumor tissues andral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transcript is predominantly expressed in all breast tissue
samples and followed by SSTR1, SSTR3 and SSTR4 [14].
Additionally, Pfeiffer et al., reported that SSTR2 and
SSTR5 as the predominant subtypes expressed in pri-
mary breast tumors [15]. Moreover, MCF-7 cells with
over-expression of SSTR2 display diminished rate of cell
proliferation [16]. SSTR2 exerts its anti-proliferative ef-
fect by either activating or suppressing various signal
transduction pathways including mitogen activated pro-
tein kinases (MAPK), phosphatidylinositol-3-protein kin-
ase (PI3K)/AKT, phosphotyrosine phosphatases such as
PTP1 and PTP2 [17-21]. The activation of multiple sig-
naling pathways consequently leads to the induction of
cell cycle arrest via activation of cyclin dependent kinase
inhibitor (p27Kip1) as well as apoptosis. SSTRs positive
tumors are less malignant with higher survival rate
whereas the lack of SSTRs expression has also been asso-
ciated with poorly differentiated and invasive tumor [22].
This could partly be attributed to the over-expression of
epidermal growth factor receptors (EGFRs) in breast can-
cer that are associated with poor prognosis and patient
survival rate [13,23,24]. Importantly, in MCF-7 cells, over-
expression of SSTR2 resulted in suppression of EGFR
expression [16]. Further in support, our recent studies
have also described attenuation of EGFR phosphorylation
and suppression of tumor promoting signals in breast
cancer cells as well as in human embryonic kidney (HEK)-
293 cells transfected with SSTR1 or SSTR5 [13,20,21].
Like SSTRs, opioid receptor (ORs), namely μ, δ and κ
are also the members of GPCR family. SSTRs and ORs
share >40% structural homology and are well expressed
in various breast cancer cells as well as in solid breast
tumor tissues [25,26]. ORs are well characterized for
their analgesic role and like SSTRs have recently been
reported as negative regulators of cell growth in various
tumors including, prostrate, lung, kidneys and breast
cancer [27-29]. It has been previously shown that >50%
of invasive ductal carcinomas are positive for opioid
peptide like immunoreactivity [30]. Furthermore, human
adrenocarcinoma and breast cancer cell lines exhibited
the binding site for opioids. The opioid agonist [D-Ala
2,
D-Leu
2] enkephalin (DADLE), displayed inhibition of cell
proliferation in a concentration dependent manner and
was reversed in the presence of antagonist naloxone
[29,31,32].
SSTR and OR subtypes constitute functional heteromeric
complexes within same sub-family and other GPCRs and
modulate receptor trafficking and signaling properties
[25,33-37]. SSTR5 and dopamine receptor 2 (D2R) hetero-
dimerization synergistically control the hyper-secretion of
growth hormone and prolactin in pituitary adenomas
[38,39]. These observations have led to the application of
new chimeric molecules of D2R and SSTR5 for thetreatment of pituitary tumor acromegaly [1,38-40]. Further-
more, SSTR2 interfere with PI3K signaling via disruption of
the SSTR2/p85 subunit complex consequently inhibiting
the cell proliferation and tumor growth [17]. HEK-293 cells
co-transfected with SSTR2 and μOR constituted stable
heterodimers thereby regulating the receptor phosphoryl-
ation, internalization and desensitization [15]. Whether
SSTR2 functionally interacts with ORs in breast cancer cells
expressing these receptors endogenously and function in
similar manner as described in heterologous system is
largely elusive. We hypothesize that the simultaneous acti-
vation of SSTR2 and ORs may exert pronounced anti-
proliferative effect via changes in signaling pathways in
breast cancer cells. Multiple studies have documented that
estrogen upregulated the expression of SSTR2 mRNA and
protein via ER in T47D and ZR75-1 (ER + ve) breast cancer
cells. These findings may anticipate the role of SSTR2 in
ER responsiveness of breast cancer [41-43]. However,
SSTR2 and OR subtypes mediated effect on signaling path-
ways in part are dependent on the presence of ER in breast
cancer cells is still elusive. In the present study, we focus to
determine the expression of SSTR2 and ORs and the
changes in receptor expression and signaling pathways
upon treatment with receptor specific agonist in human
breast cancer cell lines; MCF-7 (ER + ve), MDA-MB231
(ER-ve), and T47D (ER + ve).
Materials and methods
Chemicals and reagents
SSTR2 specific non-peptide agonist L-779,976 was pro-
vided by Dr. Rohrer from Merck & Co. Specific agonists
for μOR (DAMGO), δOR ([D-Ala2]- Deltorphin II) and
κOR (±)-U-50488 hydrochloride) were purchased from
Tocris Biosciences (Ellisville, MO). Polyclonal rabbit
anti-SSTR2 antibody was developed in our laboratory
[44,45]. The antibodies against ORs (μ, δ and κ), phos-
phorylated and total-EGFR were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal
antibodies against phosphorylated and total-ERK1/2,
p38, PI3K, AKT, PTEN and p53 were purchased from
Cell Signaling Technology (Mississauga, ON). Goat anti-
rabbit or donkey anti-goat Alexa Fluor-488 and Alexa
Fluor-594 were purchased from Invitrogen (Burlington,
ON). Annexin-APC V was obtained from BD Biosciences
(Mississauga, ON). All experiments were performed in
compliance with Office of Research and Biosafety Com-
mittee guidelines at the University of British Columbia.
Cell lines and culture
Human breast cancer cell lines, MCF-7 and T47D (ER + ve)
were maintained in RPMI 1640 medium supplemented with
10% (v/v) fetal bovine serum (FBS) and 1% antibiotic (peni-
cillin/streptomycin) at 37°C, 5% CO2 as previously de-
scribed [4,13]. MDA-MB231 (ER-ve) cells were maintained
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FBS and 1% antibiotic (penicillin/streptomycin) at 37°C in
a CO2 free atmosphere.
Indirect immunofluorescence immunocytochemistry
Breast cancer cells were processed for indirect immuno-
fluorescence immunocytochemistry as described earlier
[13,21]. Briefly, cells were washed and fixed with 4%
paraformaldehyde and followed by treatment with Triton
X-100 for 10 min at room temperature. The cells were
incubated with anti-goat μ, δ, and κ -OR (1:300) primary
antibodies overnight at 4°C and followed by incubation in
goat-anti-rabbit Alexa 488 (1:700) conjugated secondary
antibodies for 1 h at room temperature for final color de-
velopment. The cells were viewed and photographed on a
Leica DMLB microscope attached to a Retiga 2000R cam-
era. The specificity of immunoreactivity was determined
in absence of primary antibodies or in presence of pre-
immune serum as described earlier [45].
Western blot analyses
Membrane extracts as well as whole cell lysate prepared
from control and treated cells were fractionated on SDS-
PAGE as described previously [13,21]. To determine the
receptor expression in membrane extracts, blots were
incubated with primary antibodies against SSTR2 (1:400)
and μ, δ and κ-OR (1:500). The status of signaling mole-
cules were examined by incubating the immunoblots
with antibodies against phosphorylated and/or total
extracellular regulated protein kinase 1/2 (ERK1/2), p38,
PI3K, AKT, PTEN and p53 (1:1000). Membrane was
incubated with peroxidase conjugated secondary anti-
bodies respectively. The bands were detected using che-
miluminescence in accordance to the manufacturer’s
instructions (Amersham Biosciences). Images were cap-
tured using the Alpha Innotech FluorChem 8800 gel box
imager and FluorChem software was used to quantify
the blots. Tubulin was used as the loading control.
Co-Immunoprecipitation (Co-IP)
Breast cancer cells were treated with specific agonists for
SSTR2, L-779,976 (10 nM) and μOR (DAMGO; 1 μM),
δOR (Deltorphin-II; 1 μM), or κOR (U50488HCl; 1 μM)
alone or in combination for 15 min at 37°C. 200 μg of total
membrane protein was solubilized in 1 ml of radio-
immune precipitation assay (RIPA) buffer (150 mM NaCl,
50 mM Tris–HCl, 1% Nonidet P-40, 0.1% SDS, 0.5% so-
dium deoxycholate, pH 8.0) for 1 h at 4°C as described
earlier [20,21]. Samples were incubated with anti-SSTR2
antibody (1:200) for immunoprecipitation and purified
with protein A/G-agarose beads overnight at 4°C. Purified
proteins were subjected to 7% SDS-PAGE and probed for
the expression of ORS using anti-μ, δ and κ-OR antibodies
(1:500) respectively as described previously [20,21].Flow cytometry analysis for apoptosis/necrosis
Cells were harvested and treated with L-779,976,
DAMGO, Deltorphin-II, or U50488HCl alone and/or in
combination for 30 min at 37°C. Annexin V-APC stain-
ing was performed according to the manufacturer’s
protocol (BD Biosciences). Cells were washed twice with
cold PBS and resuspended in 1X binding buffer (0.1 M
Hepes, pH 7.4, 1.4 M NaCl, 25 mM CaCl2) at a cell dens-
ity of 1 × 105cells/ml. Annexin V-APC and propidium iod-
ide were added to the cell suspension for 15 min. Prior to
flow cytometry, 400 μl of 1X binding buffer was added and
cells were analyzed using FACS Calibur flow cytometer
(Becton Dickinson, San Jose, CA). A minimum of 10,000
events were recorded for each sample. Cells positive for
Annexin V-APC were identified as apoptotic whereas cells
positive for both Annexin V-APC and propidium iodide
were characterized as necrotic.
Statistical analysis
The changes in the expression of proteins were quantified
using ANOVA and post hoc Dunnett’s or Bonferroni’s
tests. Statistical analysis was performed using GraphPad
Prism 4.0 to determine the significant changes. Significant
statistical differences were taken at *p < 0.05. Results are
presented as mean ± SEM from three independent experi-
ments (n = 3).
Results
Comparative distribution of SSTR2 and ORs in MCF-7,
MDA-MB231 and T47D cells
SSTR2 and ORs expression at the cellular levels and in
membrane fractions was accomplished by immunofluores-
cence immunocytochemistry and western blot analysis
respectively. MCF-7 cells, displayed strong membrane ex-
pression of SSTR2 and μ, δ, κ-ORs whereas intracellular
expression of SSTR2 was weak than the ORs (Figure 1A).
In MDA-MB231 cells, SSTR2 and μ, δ and κ-ORs like im-
munoreactivity was observed at the cell surface with a
dominant expression of δ and κOR, whereas, the receptors
expression in the cytoplasmic compartment was compar-
able (Figure 1A). In contrast, T47D cells displayed strong
expression of SSTR2 and μ, δ, κ-ORs at the cell surface as
well as intracellularly (Figure 1A).
To support the cellular distribution by immunocyto-
chemistry receptor like immunoreactivity was also con-
firmed using Western blot analysis. As shown in Figure 1B,
SSTR2 was well expressed at the expected molecular size
of ~57 kDa with relatively higher expression in MDA-
MB231 cells in comparison to MCF-7 and T47D. The
expression level of SSTR2 was comparatively less in T47D
cells than MCF-7 and MDA-MB231 cells. In contrast, μOR
(~50 kDa) and κOR (~46 kDa) were well expressed in
MCF-7 cells. Conversely, the expression of κOR in mem-
brane extract prepared from MDA-MB231 and T47D cells
Figure 1 Differential expression of SSTR2 and μ, δ, κ-ORs in human breast cancer cells. (A) Indirect immunofluorescence staining showing
membrane (non-permeabilized, NP) and intracellular (permeabilized, P) expression of SSTR2 and μ, δ, κ-ORs in breast cancer cells. In the
representative panels receptor expression at the cell surface is indicated by arrows whereas arrowheads indicate intracellular expression.
(B) Cell membrane extracts obtained from MCF-7, MDA-MB231 and T47D breast cancer cells were subjected to Western blot analysis and probed
with specific primary antibodies to detect the receptor expression. The immunoblots show differential expression of SSTR2 (~57 kDa) and μ
(~50 kDa), δ (~48 kDa), κ (~46 kDa)-ORs in a cell specific manner. Histogram represents densitometric analysis of the receptor expression
normalized by using tubulin as loading control. Results are expressed as mean ± SEM (n = 3). **p < 0.01, MCF-7 vs. MDA-MB231 or T47D cells;
##p < 0.01; MDA-MB231 vs. T47D. Scale bar 10 μm.
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(~48 kDa) was comparable in all three cell lines. These
observations indicate cells-specific expression of SSTR2
and ORs.
SSTR2 and ORs modulate MAPKs in a cell-specific manner
We next determined whether receptor activation regu-
late MAPKs (ERK1/2 and p38) in breast cancer cells. In
MCF-7 cells, L-779,976, DAMGO and Deltorphin-II
alone inhibit the phosphorylation of ERK1/2 (p-ERK1/2)
(Figure 2A). Furthermore, L-779,976 in the presence of
DAMGO or Deltorphin-II displayed p-ERK1/2 com-
parable to control. In contrast, U50488HCL, alone or
in combination with L-779,976 significantly elevated p-
ERK1/2 in MCF-7 cells (Figure 2A). In MDA-MB231
cells, L-779,976 alone had no significant effect on p-
ERK1/2. DAMGO alone induced p-ERK1/2 whereas in
combined treatment with L-779,976 decreased p-ERK1/2.
In contrast, Deltorphin-II alone had no significant effect
on p-ERK1/2 whereas in combination with L-779,976
enhanced the levels of p-ERK1/2 in MDA-MB231 cells
(Figure 2A). Furthermore, in MDA-MB231 cells the acti-
vation of κOR enhanced p-ERK1/2 which was significantly
decreased to the control level upon combined treatmentFigure 2 MAPKs (ERK1/2 and p38) are modulated in a receptor and c
MDA-MB231 and T47D cells following treatment with SSTR2 and ORs agon
analysis and probed for phospho-and total ERK1/2 and p38 (1:1000). (A) Im
ERK1/2 in cell-specific manner. (B) Immunoblots displaying changes in the
cancer cells. SSTR2 and ORs activation inhibited p38 phosphorylation upon
levels of ERK1/2 using densitometric analysis. The data presented here is a
Significant difference was considered at *p < 0.05 vs. control.with SSTR2 agonist L-779,976. In T47D cells, L-779,976
maintained p-ERK1/2 comparable to control. The acti-
vation of μOR displayed comparable p-ERK1/2 but signi-
ficantly increased in combination with L-779,976. The
status of p-ERK1/2 was not changed upon activation of
δOR alone whereas expression level was diminished
significantly in presence of L-779,976 and Deltorphin-II.
Activation of κOR alone had no effect on p-ERK1/2 how-
ever simultaneous activation of SSTR2/κOR inhibited p-
ERK1/2 when compared to control (Figure 2B).
In addition to ERK1/2, in tumor cells, p38 is a crucial
mediator of apoptosis, cell-cycle arrest, cell differenti-
ation and tumor suppression [46,47]. The pro- and/or
anti-apoptotic role of p38 is attributed to the cell-type
and stimuli. Of note, p38 phosphorylation remained
comparable to control in MCF-7 cells upon treatments
with SSTR2 and ORs agonists alone or in combination
(Figure 2B). Unlike MCF-7 cells, the p-p38 was not
detected in MDA-MB231 and T47D cells across all indi-
cated treatments. Collectively, these data suggest that
basal expression of p-p38 is relatively higher in MCF-7
cell in comparison to MDA-MB231 or T47D cells with-
out any discernible changes upon SSTR2 and ORs
activation.ell-specific manner. Whole cell lysates obtained from MCF-7,
ists alone and/or in combination were subjected to western blot
munoblots illustrating agonist mediated changes in phosphorylated
phosphorylation of p38 upon specific agonist treatments in breast
indicated treatment. Histograms depict changes in the expression
representation mean ± SEM of three independent experiments.
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The aberrant activation and/or mutations in PI3K are
associated with tumor growth and failure of hormonal
therapy [48-50]. Accordingly, we next determined the
status of phosphorylated PI3K/AKT in control and cells
treated with SSTR2 and ORs specific agonists. No sig-
nificant changes in the status of PI3K phosphorylation
was observed in all cell lines upon indicated treatments,
albeit lower levels of p-PI3K when compared to control
(Figure 3A). Furthermore, irrespective to treatment and
cell lines the status of AKT phosphorylation was without
any significant changes across all treatments in all three
breast cancer cells as indicated (Figure 3A).
SSTR2 and ORs modulate tumor suppressor proteins
PTEN and p53 in cell dependent manner
Tumor suppressor proteins, PTEN and p53 serve as
negative regulators of cell proliferation in breast cancer
and mutations in PTEN and p53 are often associated
with the activation of AKT cell survival pathway [49]. In
MCF-7 cells, L-779,976 alone significantly enhanced the
phosphorylation of PTEN whereas DAMGO alone or in
combination with L-779,976 had no effect on p-PTEN
(Figure 4A). Upon treatment with Deltorphin-II alone
MCF-7 cells displayed elevated p-PTEN however co-Figure 3 Activation of SSTR2 and ORs modulate PI3K/AKT cell surviva
the expression of PI3K (A) and AKT (B) in MCF-7, MDA-MB231 and T47D ce
exhibited no discernible changes in phosphorylation of PI3K and AKT, thus
represent the densitometric analysis of PI3K/AKT expression in different tum
triplicate experiments.activation of SSTR2 and δOR resulted in significant in-
hibition of p-PTEN comparable to control. Furthermore,
in presence of U50488HCl alone or in combination with
L-779,976 the status of p-PTEN was without any signifi-
cant effect in MCF-7 cells (Figure 4A). Conversely, in
MDA-MB231 cells there was no discernible change in p-
PTEN across all the treatments as indicated. In T47D
cells, L-779,976 alone and in combination with DAMGO
significantly increased p-PTEN whereas DAMGO alone
enhanced PTEN phosphorylation insignificantly different
than the control. Furthermore, Deltorphin-II alone and
in combination with L-779,976 displayed significant in-
crease in the p-PTEN. In T47D cells, κOR agonist
resulted in significant activation of PTEN whereas such
effect was not significantly different from control upon
synergistic activation of SSTR2 and κOR (Figure 4A).
As shown in Figure 4A, MCF-7 displayed no discernible
changes in the expression of p53 across all the treatments.
In contrast, in MDA-MB231 cells, L-779,976 alone was
without any effect on p53 expression. DAMGO alone
enhanced the expression of p53 significantly whereas
in combination with L-779,976, p53 level was similar to
the control. Deltorphin-II alone and in combination with
L-799,796 significantly elevated the levels of p53. Further-
more, p53 expression was unchanged upon activation ofl pathway. Representative western blots illustrating the changes in
lls. Activation of SSTR2 and ORs individually or simultaneously
maintaining the status of PI3K/AKT at control levels. Bar graphs
or cells. The data presented are a representation of
Figure 4 Tumor suppressor proteins PTEN and p53 are modulated in cell and receptor specific manner in tumor cells. Representative
immunoblots showing the effect of SSTR2 or ORs activation on the expression of PTEN (A) and p53 (B) in MCF-7, MDA-MB231 and T47D cells
respectively. (A) The expression of PTEN is enhanced in MCF-7 as well as T47D cells; however the MDA-MB231 cells displayed no discernible
changes in the levels of PTEN. (B) The expression of p53 was in a receptor and cell-specific manner. Note the comparable changes in PTEN and
p53 expression in MCF-7 and T47D cells. Histograms illustrate densitometric analysis of PTEN and p53 levels using tubulin as the loading control.
The results presented here are representation of mean ± SEM, n = 3. Significant difference was considered at *p < 0.05 vs. control.
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nificant increase in p53 expression in MDA-MB231 cells
(Figure 4B). In T47D cells, L-779,976 alone and in com-
bination with either DAMGO or Deltorphin-II exhibited
no change in p53 expression. In contrast, DAMGO and
Deltorphin-II alone significantly enhanced the p53 ex-
pression in comparison to the control. U50488HCl alone
did not affect p53 expression however, in combination
with L-779,976, the p53 levels significantly decreased
(Figure 4B). Taken together these observations suggest
that SSTR2 and ORs upregulated the PTEN and p53
expression in a receptor and cell dependent manner.
SSTR2 and ORs induced early apoptosis and predominant
cytostatic effect in cell dependent manner
The anti-proliferative effect of SSTR2 is mediated via two
different mechanisms; cytostatic and cytotoxic. Accord-
ingly, applying flow cytometry, we investigated the cellular
response upon receptor specific agonist treatments. The
results indicated apoptotic (9.05%) and necrotic (19%)
cells in control MCF-7 cells whereas upon single treat-
ment with L-779,976 number of the cells displaying apop-
tosis and necrosis was enhanced (14.5% and 23.4%
respectively) (Figure 5A). In presence of DAMGO alone
or with L-779,976 cells displayed higher extent of necrosis
(25% and 27.8% respectively) without any significantchanges in apoptosis (11.8% and 12%). Furthermore, the
number of cells displaying apoptosis and necrosis was
enhanced upon combined treatment with L-779,976 and
Deltorphin-II (12% and 26.7%) than Deltorphin-II alone
(9 and 23.6%, respectively). In contrast, the activation
of κOR with U50488HCl alone caused higher necrosis
(29.9%), but was decreased to 23.4% upon combined treat-
ment with L-779,976 whereas cells entering apoptosis was
limited to ~10% (Figure 5A).
As illustrated in Figure 5B, MDA-MB231 cells upon
treatments with SSTR2 or μ, δ and κ-ORs agonists alone
or in combination displayed <4% of apoptotic cell popula-
tion. Conversely, cells undergoing necrosis increased
(12.4%) upon treatment with L-779,976 alone in compari-
son to the control (10.8%). DAMGO alone enhanced the
necrotic cells (13.5%) whereas upon combined treatment
with L-779,976, the number of cells going through necrosis
were enhanced to 15.3% in MDA-MB231 cells (Figure 5B).
Deltorphin-II alone enhanced the necrosis to 16%; how-
ever, combined treatment with L-779,976 decreased necro-
sis to 12.9%, similar to that seen with L-779,976 alone
(12.4%). Similarly, treatment with U50488HCl led to 14.7%
necrosis and was decreased to 11.6% upon combined treat-
ment with L-779,976 (Figure 5B).
In basal condition T47D cells number of the cells
going through apoptosis and necrosis cells were 3.65%
Figure 5 (See legend on next page.)
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Figure 5 Representative flow cytometry analysis displaying apoptosis and necrosis after exposure to SSTR2 and OR agonist in breast
cancer cells. Cells were harvested and treated with SSTR2 or ORs specific agonists alone and in combination for 30 min at 37°C as described in
Material and Method section. The percentage of apoptosis (lower right quadrant) and necrosis (upper right quadrant) was evaluated in MCF-7
(A), MDA-MB231 (B) and T47D (C) cells upon treatment as indicated. Flow cytometry profile illustrating APC-Annexin V staining on X-axis whereas
PI staining on Y-axis. A minimum of 10,000 events were recorded for each sample.
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779,976 enhanced the apoptosis (11.5%), however necro-
sis was elevated (34%) when compared to the control.
Interestingly, upon treatments with DAMGO, alone or
in combination with L-779,976, the population of nec-
rotic cells (36.9% and 38%) was enhanced significantly as
compared to the early apoptotic cells (8.79% and 7.37%).
Deltorphin-II alone or in combination with L-779,976
displayed higher necrosis (40.7% and 36.7%) than apop-
tosis (5.7% and 7.62%) (Figure 5C). Of note, combined
treatment of U50488HCl and L-779,976 markedly in-
creased the necrosis (52.4%) whereas exhibited only
4.2% apoptosis (Figure 5C). These data indicate that ER
+ ve cells (MCF-7 and T47D) are more susceptible to
necrosis upon simultaneous activation of SSTR2 and
ORs than ER-ve cells (MDA-MB231).
Expression of ORs in SSTR2 immunoprecipitate is cell and
receptor-specific in tumor cells
Previous studies using HEK-293 cells have demonstrated
that ORs and SSTR2 constituted functional heterodimers
with enhanced signaling properties [15]. To decipher the
underlying mechanism by which SSTR2/ORs functionally
interact in tumor cells expressing these receptors endogen-
ously, SSTR2 immunoprecipitate was processed for the ex-
pression of ORs by CO-IP. In MCF-7 cells, SSTR2/μOR
exists in a heteromeric complex at the expected molecular
size of ~120 kDa in control as well as upon activation of
both receptors independently (Figure 6A). However, with
combined treatment of L-779,976 +DAMGO, there was
significant loss in SSTR2/μOR complex (Figure 6A). In
MDA-MB231 cells, complex formation of SSTR2/μOR
was weak in basal state. The SSTR2/ μOR complex was
enhanced significantly upon activation of SSTR2 and the
receptor heterodimerization was lost upon treatments
with DAMGO alone or in combination with L-779,876
(Figure 6A). SSTR2 immunoprecipitate prepared from
control T47D cells was devoid of μOR expression. How-
ever, upon treatments with L-779,876 or DAMGO alone or
in combination, SSTR2 immunoprecipitate displayed μOR
expression at the expected size of ~120 kDa (Figure 6A).
In comparison to control, the heterodimerization
between SSTR2/δOR strengthened upon treatments with
specific agonists in MCF-7 cells (Figure 6B). In contrast,
MDA-MB231 cells in basal condition displayed strong
SSTR2/δOR complex formation and led to the disso-
ciation upon agonists treatment (Figure 6B). In T47Dcells, no interaction between SSTR2/δOR in basal as
well as upon treatment with L-779,976 was seen. How-
ever, upon treatments with Deltorphin-II alone or in
combination with L-779,976, cells exhibited significant
expression of δOR in SSTR2 immunoprecipitate.
SSTR2 immunoprecipitate prepared from control and
U50488HCl treated MCF-7 cells were devoid of κOR ex-
pression (Figure 6C). Whereas cells treated with specific
agonists for SSTR2 alone or in combination with κOR
induced the complex formation between SSTR2/κOR
(Figure 6C). In MDA-MB231 cells, activation of SSTR2
alone displayed increased complex formation between
SSTR2/κOR however, upon treatments with U50488HCl
alone or in combination with L-779,976; the expression
of κOR in SSTR2 immunoprecipitate was comparable to
control (Figure 6C). Conversely, T47D cells, exhibited com-
parable expression of κOR in SSTR2 immunoprecipitate in
control as well as upon treatment with SSTR2 agonist.
However in comparison SSTR2/κOR complex formation
increased upon treatment with κOR agonist alone and in
combination with SSTR2 agonist (Figure 6C). These results
strengthen the concept of ligand, cell dependency in pos-
sible heterodimerization between SSTR2 and ORs respect-
ively. The specificity of immunoreactivity was confirmed in
absence of primary antibodies and incubation with second-
ary antibodies alone as previously described [20,21].
EGFR phosphorylation in breast cancer cells is abolished
in presence of synergistic activation of SSTR2 and ORs
The observations that breast tumor progression associated
with EGFR over-expression, phosphorylation and homo-
and/or heterodimerization suggested a crucial role of
EGFR in breast cancer [13,20,21,51]. In order to identify
the possible link between EGFR and SSTR2/ORs we deter-
mined the effect of SSTR2 and ORs activation on EGFR
phosphorylation. In MCF-7 cells, SSTR2 agonist L-779
,976 alone or in combination with ORs agonists decreased
the phosphorylation of EGFR although not significantly
different than the control (Figure 6D). Interestingly,
MDA-MB231 and T47D cells displayed no EGFR phos-
phorylation across all treatments (Figure 6D). These data
indicate that SSTR2 and ORs together maintained EGFR
phosphorylation comparable to control in MCF-7 cells.
The inhibition of EGFR phosphorylation is crucial in
breast cancer, however, whether the changes seen in the
downstream signaling pathways are in-part due to the lack
of EGFR phosphorylation needs further investigation.
Figure 6 Agonist dependent complex formation between SSTR2/ORs and inhibition of EGFR phosphorylation. Co-immunoprecipitation
showing the expression of μOR (A), δOR (B) and κOR (C) in SSTR2 immunoprecipitate obtained from MCF-7, MDA-MB231 and T47D cells
following indicated treatment. The agonist-induced heterodimerization between SSTR2 and μOR, δOR or κOR is receptor and cell-specific. (D)
Western blot showing SSTR2 and ORs mediated inhibition of EGFR phosphorylation in breast cancer cells. MCF-7 cells displayed EGFR
phosphorylation comparable to control without any discernible difference upon indicated treatment. Note the lack of EGFR phosphorylation in
MDA-MB231 despite basal EGFR expression whereas T47D cells were devoid of EFGR expression and phosphorylation. Tubulin was used as a
loading control.
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In the present study we unfold the effects of activation of
SSTR2 and ORs alone or in combination on signaling cas-
cades and cell proliferation in human breast cancer cells
including MCF-7, MDA-MB231 and T47D. The activation
of SSTR2 and ORs modulate the MAPK pathway and in-
hibit the cell survival PI3K/AKT signaling molecules and
thereby enhancing the expression of tumor suppressor
proteins PTEN/p53 in cell and possibly ER dependent
manner. These changes in modulation of downstream sig-
naling were corroborated using flow cytometry describing
the nature of cell death which showed eminent necrosis
indicating the anti-proliferative effect of SSTR2 and ORs
in breast cancer cells. In addition, our results describe re-
ceptor and agonist dependent expression of ORs in SSTR2
immunoprecipitate suggesting that SSTR2 and ORs might
interact as heterodimers. In tumor cells, activation of
SSTR2 and ORs inhibit the phosphorylation of EGFR.
Although, there is growing understanding for the synergis-
tic effect of many GPCRs in cells transfected with one ormore receptor, this is the first comprehensive description
of SSTR2 and ORs in tumor cells expressing both receptor
subtypes endogenously. Our results demonstrate agonist
dependent internalization of SSTR2 and ORs in receptor
and cell-specific manner. The activation of SSTR2 and
ORs modulate MAPKs (ERK1/2 and p38) and the expres-
sion of tumor suppressor proteins, PTEN and p53 re-
sulting in the suppression of PI3K/AKT pathway. We
further correlated the effects of SSTR2/ORs mediated
signaling with the functional consequences by measuring
the apoptosis and necrosis using flow cytometry. The re-
sults described here also revealed heterodimerization be-
tween SSTR2/OR and inhibition of EGFR phosphorylation.
Our findings for the first time highlight the molecular
mechanisms for the role of SSTR2 and ORs mediated
antagonism of tumorigenic signaling pathways in human
breast cancer cells in receptor dependent manner.
The co-expression of given receptors is a pre-requisite
for heterodimerization and this was further supported
by expression of ORs in SSTR2 immunoprecipitate.
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our results showed that SSTR2 exist as pre-formed
heterodimers with μ, δ and κ-ORs in breast cancer cells in
receptor and cell-specific manner [15]. Moreover, SSTR2
formed heterodimers with δ and κORs in agonist and cell
specific manner. Our results strengthen the concept that
the activation of one receptor is capable of inducing recep-
tor complex formation while second protomer may either
stabilize or dissociate the heteromeric complex.
There is preponderance of evidence suggesting the
mechanistic significance of GPCRs expression, traffick-
ing and heterodimerization in modulation of down-
stream signaling pathways [18,20,21,52]. Studies suggest
that the activation of ERKs and p38 in various cancer
cells lead to aberrant cell proliferation [53]. Consistent
with the existing data, activation of SSTR2 or ORs alone
or in combination inhibit ERK1/2 in MCF-7 and T47D
cells more than the MDA-MB231 cells [28]. Interest-
ingly, p38 mediated anti-apoptotic effects typically seen
in breast cancer are remarkably diminished in MDA-
MB231 and T47D cells upon activation of SSTR2 and
ORs. Surprisingly, T47D and MCF-7 cells are ER + ve,
but the cellular response to SSTR2/OR activation and
inhibition of p38 was pronounced in T47D cells. Al-
though such discrepancy in inhibition of p38 may be
attributed due to the changes in other isoforms of p38
in addition to the difference in the origin of these cells;
MCF-7 (adenocarcinoma) and T47D (ductal carcinoma).
However, the intensity of expression levels of ER in these
cells cannot be avoided from the discussion and future
studies are warranted in this direction. Moreover results
described here are consistent with the previous studies
showing an enhanced pro-apoptotic effect in MCF-7
cells over-expressing SSTR2 [16].
PI3K/AKT hyper-phosphorylation, uncontrolled breast
cancer progression and resistance to hormonal therapy
is well established [48,54]. In all three tumor cell lines,
the status of phosphorylated PI3K/AKT was not signifi-
cantly different from the control. Moreover, this block-
ade of PI3K/AKT specifically in MCF-7 and T47D cells
was accompanied by an increased expression of tumor
suppressor PTEN supporting the notion that loss of
PTEN is due to PI3K/AKT activation [48,49]. Notably,
the activation of PI3K/AKT induced ERα expression in
MCF-7 cells and spared them from tamoxifen mediated
apoptosis [54]. This suggests that enhanced PTEN ex-
pression, predominantly in ER + ve MCF-7 and T47D
cells as described here may alleviate TAM resistance.
The activation of PI3K/AKT has also been shown to
down regulate p53 induced apoptosis in breast cancer
[55]. Previous reports suggested that in MCF-7 cells with
over-expression of ErbB2 significantly activate PI3K and
decreased the expression of p53, however, this effect was
reversed upon blocking PI3K pathway [56]. Taken intoconsideration, enhanced expression of p53 and compar-
able activation of PI3K/AKT to control also highlight
novel function of SSTR2/ORs in breast cancer cells.
Given the receptor dependent role, SSTR2 and ORs
regulating the MAPK and PI3K/AKT pathways in breast
cancer cells is an indication of inhibition of EGFR func-
tions. This speculation is supported by aggressive tumor
proliferation in breast cancer displaying over-expression
and hyper-phosphorylation of EGFR [24,51,57]. An in-
verse relationship between EGFR and ER has been
established. Moreover, the absence of ER expression in
human breast cancer cell lines including MDA-MB231
is associated with higher levels of functional EGFR pro-
tein and mRNA [58]. In parallel to previous studies, our
data revealed complete blockade of EGFR phosphoryl-
ation upon activation of SSTR2 and ORs in MDA-
MB231 and T47D cells [59,60]. Conversely, in MCF-7
cells, EGFR phosphorylation was lower than the control
suggesting that endogenous EGFR phosphorylation is
relatively higher in comparison to other cancer cells. We
anticipate that the SSTR2/ORs mediated inhibition of
EGFR phosphorylation possibly arrest the downstream
MAPK and PI3K/AKT signaling thereby inducing the
expression of tumor suppressor PTEN and p53. This
supposition is further supported by our recent studies
showing the inhibition of EGFR phosphorylation by acti-
vation of SSTR1 or SSTR5 leading to the pronounced in-
hibition of cell proliferating signals in HEK-293 cells
[20,21]. Moreover, the physiological response of tumor
cells upon activation of SSTR2/ORs parallel the changes
seen in downstream signaling. FACs analysis revealed
higher necrotic cell population (>25%) in MCF-7 and
T47D cells than MDA-MB231 cells. The early apoptosis
increased upon specific treatment, however, was limited
to <5%. Consistent with previous studies, our observa-
tions suggest a much pronounced cytotoxic role of
SSTR2 and ORs in breast cancer cells as described previ-
ously [16]. These observations warrant concentration
and time dependent effect of SSTR2/OR agonist on
apoptosis and necrosis and further studies are in pro-
gress in this direction.
Targeting EGFR hyperactivity and PI3K/AKT pathways
have been the therapeutic approach for the treatment of
breast cancer. SSTR2 agonists have been clinically used
for the treatment of acromegaly and pancreatic tumors,
whereas ORs are emerging new members of GPCR fam-
ily for their anti-proliferative role in various tumors.
Therefore, targeting SSTR2 and specific ORs could pos-
sibly be a better therapeutic approach in breast cancer
treatment. In addition to the anti-proliferative role, the
analgesic role of ORs in the treatment of breast cancer
cannot be neglected since patients undergoing chemo-
therapy are known to experience pain. Previously, SST
analogs have been proven to be effective in pain relief in
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worth investigating the dual role of ORs as a tumor sup-
pressor and analgesic agent in the treatment of breast
cancer in synergism with SSTR subtypes. Our observa-
tions uncovered the new role of SSTR2 and ORs in com-
bination in regulating the key tumor promoting signals
in breast cancer cells. To determine whether such effect
is partly due to direct functional interaction between
these receptors further studies are in progress in this dir-
ection. Taken together, results presented in this study in
part may be due the presence and expression intensity
of ER. Furthermore, additional studies are essential to
support whether knocking down ER in MCF-7 and
T47D and transient expression of ER in MDA-MB231
cells display comparable changes. In conclusion, this is
the first comprehensive study unveiling the molecular
mechanisms of SSTR2/ORs mediated anti-proliferative
signaling with novel therapeutic implications in breast
cancer treatment.
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